Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer (LPC).

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 175-175
Author(s):  
Frederick S. Albright ◽  
Neeraj Agarwal ◽  
William Thomas Lowrance ◽  
Robert A Stephenson ◽  
Anitha Alex ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Registry ◽  
Death Certificate ◽  
Population Data ◽  
Expected Number ◽  
Degree Relative ◽  
Increased Risk ◽  
History Of ◽  
Lethal Prostate Cancer

175 Background: There are few published reports of relative risk (RR) for LPC based on family history of prostate cancer (PC) lethality. This study provides LPC RR using complete LPC family history data obtained from a statewide Cancer Registry linked to a genealogy database. Methods: The Utah Population Data Base (UPDB), which includes a statewide SEER cancer registry, includes 1,192,768 individuals with at least 12 of their 14 immediate ancestors. All males (probands) with specific LPC constellations were identified in the UPDB, and the observed number of LPC cases among these probands was compared to the expected number of LPC cases using internal cohort-specific rates from Utah death certificates including all deceased males with no 1st, 2nd, or 3rd degree relatives with LPC. LPC Family history was estimated for 1st degree to 3rd degree relatives for: number of LPC relatives affected, paternal versus maternal family history, and age at first PC diagnosis. Results: 3,921 individuals in UPDB were diagnosed with histologically confirmed PC, and had a Utah death certificate indicating PC as a cause of death and were designated LPC. The RR for LPC was significantly elevated with each additional first-degree relative (FDR) with LPC; even in the absence of FDR family history of LPC, significantly increased risk for LPC was observed in the presence of at least 1 LPC affected second degree relative (SDR). In the absence of positive FDR and SDR family history for LPC, there was still increased risk for LPC for males with 2 or more third degree relatives with LPC. Early age PC diagnosis in the LPC relative did not appear to affect LPC RR. Higher risks of LPC were associated with the maternal compared to the paternal lineages. Conclusions: Examination of lethal prostate cancer family history (in FDRs through TDRs) may be useful in identifying the cohort of men with prostate cancer most at risk for death from prostate cancer. Focused screening and treatment of this cohort holds potential to decrease the rates of undertreatment of lethal disease while avoiding over diagnosis and overtreatment in inconsequential disease.

Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome.

1997 ◽  
Vol 15 (4) ◽  
pp. 1478-1480 ◽  
Author(s):  
P A Kupelian ◽  
V A Kupelian ◽  
J S Witte ◽  
R Macklis ◽  
E A Klein
Keyword(s):  
Prostate Cancer ◽  
Treatment Outcome ◽  
Family History ◽  
Treatment Modality ◽  
Proportional Hazards ◽  
Positive Family History ◽  
Specific Antigen ◽  
Tumor Stage ◽  
Degree Relative ◽  
History Of

PURPOSE To determine if familial prostate cancer patients have a less favorable prognosis than patients with sporadic prostate cancer after treatment for localized disease with either radiotherapy (RT) or radical prostatectomy (RP). PATIENTS AND METHODS One thousand thirty-eight patients treated with either RT (n = 583) or RP (n = 455) were included in this analysis. These patients were noted as having a positive family history if they confirmed the diagnosis of prostate cancer in a first-degree relative. The outcome of interest was biochemical relapse-free survival (bRFS). We used proportional hazards to analyze the effect of the presence of family history and other potential confounding variables (ie, age, treatment modality, stage, biopsy Gleason sum [GS], and initial prostate-specific antigen [iPSA] levels) on treatment outcome. RESULTS Eleven percent of all patients had a positive family history. The 5-year bRFS rates for patients with negative and positive family histories were 52% and 29%, respectively (P < .001). The potential confounders with bRFS rates were iPSA levels, biopsy GS, and clinical tumor stage; treatment modality and age did not appear to be associated with outcome. After adjusting for potential confounders, family history of prostate cancer remained strongly associated with biochemical failure. CONCLUSION This is the first study to demonstrate that the presence of a family history of prostate cancer correlates with treatment outcome in a large unselected series of patients. Our findings suggest that familial prostate cancer may have a more aggressive course than nonfamilial prostate cancer, and that clinical and/or pathologic parameters may not adequately predict this course.

Abstract 3449: Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer

2015 ◽  
Author(s):  
Frederick S. Albright ◽  
Neeraj Agarwal ◽  
William T. Lowrance ◽  
Robert A. Stephenson ◽  
Lisa A. Cannon-Albright
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Complete Family ◽  
History Of ◽  
Lethal Prostate Cancer

Does a family history of adenomatous colon polyp(s) in a first-degree relative pose an increased risk of developing colon cancer?

2018 ◽  
Vol 21 (4) ◽  
pp. E8
Author(s):  
Ernestine Clements ◽  
Lena Gamble ◽  
Nathan Way ◽  
Lacy Smith ◽  
John B. Waits
Keyword(s):  
Colon Cancer ◽  
Family History ◽  
Colon Polyp ◽  
Degree Relative ◽  
Increased Risk ◽  
History Of ◽  
Relative Pose

scholarly journals Diet, Lifestyles, Family History, and Prostate Cancer Incidence in an East Algerian Patient Group

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Somia Lassed ◽  
Cláudia M. Deus ◽  
Nuno Lourenço ◽  
Abderrezak Dahdouh ◽  
Albert A. Rizvanov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Dietary Habits ◽  
Strong Association ◽  
Lifestyle Factors ◽  
Algerian Population ◽  
Increased Risk ◽  
History Of ◽  
The Relationship ◽  
Control Study

Prostate cancer (PC) is the fourth most common cancer in men and the sixth leading cause of death in Algeria. To examine the relationship between lifestyle factors, including diet, and family history and PC risk, a case-control study was performed in an eastern Algerian population, comprising 90 patients with histologically confirmed PC and 190 controls. Data collection was carried out through a structured questionnaire and statistical analysis was performed to evaluate the different variables. The data showed that consumption of lamb and beef meat and high intake of animal fat and dairy products increased PC risk. Seven to thirteen vegetables servings per week and fourteen or more servings decreased PC risk by 62% and 96%, respectively. Seven to fourteen fruit servings per week decrease PC risk by 98%. Green tea consumption reduced the risk of PC but the results were statistically borderline. Increased risk was observed for individuals with family history of PC in first and in second degree. A positive strong association was also found for alcohol and smoking intake and a dose-response relationship existed for quantity and history of smoking. This study suggests that dietary habits, lifestyle factors, and family history have influence on the development of PC in Algerian population.

scholarly journals Skin Melanoma and Subsequent Risk of Prostate Cancer: A Lithuanian Cancer Registry Study

2019 ◽  
Vol 16 (20) ◽  
pp. 3915 ◽  
Author(s):  
Ausvydas Patasius ◽  
Vincas Urbonas ◽  
Giedre Smailyte
Keyword(s):  
Prostate Cancer ◽  
General Population ◽  
Cancer Registry ◽  
Registry Study ◽  
Skin Melanoma ◽  
Expected Number ◽  
Melanoma Diagnosis ◽  
Increased Risk ◽  
The Relationship ◽  
Subsequent Risk

Emerging data indicates that melanoma may be linked to prostate cancer. We evaluated if the incidence of melanoma was associated with subsequent risk of prostate cancer (PC). We extracted data from the Lithuanian cancer registry from 1993 to 2012. We calculated the standardized incidence ratios (SIRs) for PC as a ratio of observed number of cancer cases in people with previous melanoma diagnosis to the expected number of cancer cases in the underlying general population. Therein, 95% confidence intervals for the SIRs were estimated assuming the number of observed cancer cases follows the Poisson distribution. Overall, 65 PCs were observed versus 52.5 expected (SIR 1.24; 95% CI: 0.97–1.58) within a period of 24 years. A significantly increased risk of PC was found in patients with melanoma diagnosis over 70 years (SIR 1.62; 95% CI: 1.11–2.39) and in two periods of diagnosis (SIRs 1.76 and 1.62 in 1993–1997 and 2009–2012, respectively). A significantly increased risk was also found five to nine years after melanoma diagnosis (SIR 1.58; 95% CI: 1.05–2.38). Further studies are needed to evaluate the relationship between melanoma and subsequent risk of prostate cancer.

Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death

The Prostate ◽  
2016 ◽  
Vol 77 (1) ◽  
pp. 41-48 ◽  
Author(s):  
Frederick S. Albright ◽  
Robert A. Stephenson ◽  
Neeraj Agarwal ◽  
Lisa A. Cannon-Albright
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Death ◽  
Complete Family ◽  
Relative Risks ◽  
Prostate Cancer Death ◽  
History Of ◽  
Lethal Prostate Cancer

Differences in the Distribution of Cytogenetic Subtypes Between Multiple Myeloma Patients with and without a History of Familial MGUS and Multiple Myeloma

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4000-4000
Author(s):  
Alexandra Greenberg ◽  
Margot Cousin ◽  
Celine M Vachon ◽  
Dirk Larson ◽  
Colin L. Colby ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Family History ◽  
Research Funding ◽  
Plasma Cells ◽  
Statistical Significance ◽  
Degree Relative ◽  
First Degree Relatives ◽  
Familial Tendency ◽  
Increased Risk ◽  
History Of

Abstract Abstract 4000 Background: We have previously reported that there is an increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (Vachon CM. Blood 2009 114: 785–790). There are several cytogenetic subtypes of myeloma, and there are no data on whether certain cytogenetic subtypes of myeloma are more frequently associated with familial MGUS. Methods: We studied patients with myeloma who participated in the familial MGUS study in whom presence or absence of MGUS in the first-degree relatives had been ascertained (Vachon CM. Blood 2009 114: 785–790). Probands were seen at the Mayo Clinic Hematology/Oncology practice (Rochester, MN, USA) between February 2006 and September 2007. Cytogenetic data was acquired via electronic medical record abstraction of fluorescence in-situ hybridization (FISH) lab reports, and used to categorize patients into one of nine cytogenetic subgroups: trisomy(ies), t(6;14), t(11;14), t(4;14), t(14;16), t(14;20), Mixed (those with trisomy(ies) and an IgH translocation), other cytogenetic abnormalities (in the absence of trisomy(ies) or IgH translocation), and normal (Kumar S. Blood 2012;119:2100–2105). We examined whether a difference in the distribution of the six primary cytogenetic categories of myeloma existed between probands with a family history of MGUS and/or myeloma and those without. Results and Conclusions: Of the 248 patients invited to participate, FISH data (with sufficient plasma cells) was available on 119 participants to establish the primary molecular cytogenetic classification of myeloma. All had available information regarding family history of MGUS and multiple myeloma. 27 had an affected first-degree relative with MGUS, and 92 did not. Distributions of cytogenetic subtypes in the two groups are shown in Table 1. IgH translocated MM was more common in myeloma patients who lacked an affected first-degree relative compared to those with familial MGUS (19% vs 30%, P=0.32) Interestingly, the t(11;14) subtype was more common in myeloma patients without familial MGUS compared to those with an first-degree relative with MGUS (19.6% vs 7.4%, P=0.24). The differences in Table 1 did not reach statistical significance, possibly due to the small numbers of individuals with a family history in this sample. However, the distribution (Table 1) suggests that the distribution of cytogenetic subtypes may be different in myeloma that is not associated with familial MGUS compared with myeloma in which a familial tendency is detected. IgH translocated MM appears to have a lower risk of familial tendency. Further investigation is needed to estimate the risk of familial MGUS within each cytogenetic subtype. Disclosures: Kumar: Merck: Consultancy, Honoraria; Millennium: Research Funding; Celgene: Consultancy, Research Funding; Novartis: Research Funding; Genzyme: Research Funding.

Detection of germline deleterious mutations in prostate cancer patients with use of a validated 30-gene sequencing assay.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 223-223
Author(s):  
Panagiotis J. Vlachostergios ◽  
Ana M. Molina ◽  
Himisha Beltran ◽  
David M. Nanus ◽  
Scott T. Tagawa
Keyword(s):  
Prostate Cancer ◽  
Dna Repair ◽  
Family History ◽  
Positive Family History ◽  
High Susceptibility ◽  
Degree Relative ◽  
Repair Gene ◽  
Dna Repair Gene ◽  
History Of ◽  
Gene Alterations

223 Background: Germline DNA repair gene alterations in men with metastatic prostate cancer (PC) unselected for family history of malignancy occur in a greater frequency compared to localized PC and the general population. We hypothesized that assessing heritable alterations in a broader panel of high-susceptibility genes, may be relevant for detecting familial associations with other cancers in PC patients. Methods: We examined a cohort of 52 PC patients (median age 60, range 45-80) with histologically confirmed PC (17 localized, 35 metastatic). Germline DNA was isolated from blood lymphocytes or buccal swabs, and targeted next-generation sequencing was conducted with use of a previously validated panel of 30 genes associated with an elevated risk for common cancers (Color Genomics). As a reference for gene aberration frequencies we used the Exome Aggregation Consortium (ExAC) database. Results: The majority of patients (48/52, 92%) had a positive family history of cancer in any relative. Nine deleterious pathogenic mutations were identified in germline DNA samples from 8/52 (15%) patients, affecting the following genes: APC (n = 2, 3.8%), BRCA2 (n = 2, 3.8%), CHEK2 (n = 3, 5.7%), ATM (n = 1, 1.9%), RAD51D (n = 1, 1.9%). APC mutations were significantly more frequent in our cohort compared to the ExAC database (0.3%, p < 0.001). The frequency of DNA repair gene alterations (7/52, 13.5%) was also significantly higher compared to the ExAC database (0.3%, p < 0.001). The median overall survival (OS) between patients with and without germline gene alterations was similar (81.5 versus 74 months, respectively). The presence of heritable gene alterations from the 30-gene panel was significantly more frequent in patients with a positive family history of any cancer (p < 0.001) or prostate, breast, ovarian cancer (p = 0.001) in a first degree relative. Conclusions: The use of a targeted panel of high-susceptibility cancer-associated genes in PC not only confirms the enrichment of germline mutations in men with PC. It can also reveal associations of PC with other cancers which may portend implications for treatment and prognosis.

ATM mutation carriers and family history of pancreatic cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 1529-1529
Author(s):  
Jeannie Klavanian ◽  
Dana Zakalik ◽  
Anish S Konde ◽  
Tara Rangarajan
Keyword(s):  
Pancreatic Cancer ◽  
Family History ◽  
Gene Mutations ◽  
Close Relative ◽  
Degree Relative ◽  
Mutation Carriers ◽  
Increased Risk ◽  
Age Of Diagnosis ◽  
History Of ◽  
Atm Gene

1529 Background: Multigene panel testing (MGT) is commonly utilized in patients with a personal or family history of cancer. One of the more common gene mutations identified is in the ATM gene, associated with a moderately increased risk of breast and other cancers. There are reports of an association with pancreatic cancer, however the exact risks are unclear. The aim of this study is to describe the family history of pancreatic cancer in a cohort of ATM mutation carriers, and to evaluate possible genotype/phenotype correlation. Methods: Patients who underwent MGT, between ‘13 and ‘19, and tested positive for a pathogenic/likely pathogenic ATM mutation were included in this study. Family history, with a focus on pancreatic cancer, and genetic testing results were analyzed. Results: A total of 114 patients were identified to carry an ATM mutation. Twenty-two (19.3%) individuals had a family history of pancreatic cancer in a close relative, and of those, 13 (11.4%) had an affected first degree relative, and 11 (9.6%) had an affected second degree relative. Among the families with pancreatic cancer, 20 close relatives had a personal history of pancreatic cancer, with the youngest diagnosed at age 40, the oldest diagnosed at age 91, and a mean age of diagnosis of 66.5 years. Thirteen unique variants were identified: 4 splice site, 3 missense, 3 frameshift, 1 nonsense, and 1 silent. Two families had the known high-penetrance ATM mutation, c.7271T > C (p.V2424G). Conclusions: This study describes the association of pancreatic cancer in individuals found to carry pathogenic ATM mutations. A significant proportion (19.3%) of patients had a family history of pancreatic cancer in a close relative, diagnosed as young as age 40. The mean age of diagnosis was slightly younger than the average age in the general population (age 70). As pancreatic cancer screening continues to improve, this information will be an important component to help guide cancer risk assessment and future screening recommendations for ATM mutation carriers. Additional larger studies are needed to further characterize pancreatic cancer risks in patients with ATM gene mutations.

scholarly journals Family History of Cancer and Tobacco Exposure in Index Cases of Pancreatic Ductal Adenocarcinoma

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
R. Lochan ◽  
A. K. Daly ◽  
H. L. Reeves ◽  
R. M. Charnley
Keyword(s):  
Pancreatic Cancer ◽  
Family History ◽  
Pancreatic Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Tobacco Exposure ◽  
Degree Relative ◽  
Family History Questionnaire ◽  
Increased Risk ◽  
History Of ◽  
History Of Cancer

Aim. To examine interaction between history of cancer in first-degree relatives and tobacco smoking in index patients of pancreatic adenocarcinoma.Methods. We carried out a case-control involving 113 patients with pancreatic adenocarcinoma and 110 controls over a 12-month period at the Freeman Hospital, Newcastle upon Tyne, UK. They were all administered a detailed tobacco exposure questionnaire and a family history questionnaire. We calculated cumulative tobacco exposure and risk for pancreas cancer.Results. Both smokers (OR 3.01 (95% CI: 1.73 to 5.24)) and those with a family history of malignancy (OR 1.98 (95% CI: 1.15–3.38)) were more likely to develop pancreatic cancer. Having more than one first-degree relative with cancer did not significantly further increase the risk of pancreatic cancer. Amongst pancreatic cancer cases, cumulative tobacco exposure was significantly decreased () in the group of smokers (current and ex-smokers) who had a family history of malignancy [mean (SD): 30.00 (24.77) pack-years versus 44.69 (28.47) pack-years with no such history].Conclusions. Individuals with a family history of malignancy are at an increased risk of pancreatic cancer. Furthermore, individuals with a family history of malignancy and who smoke appear to require a lesser degree of tobacco exposure for the development of pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document